Clinical trialNCT06494904RecruitingPhase 3Interventional

Standard Versus High Dose ED-Initiated Buprenorphine Induction

SponsorYale UniversityEnrollment360Opioid Use Disorder

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post randomization, and opioid withdrawal symptoms, opioid craving, and use of illicit and non-prescribed drugs.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Gail D'Onofrio, MD, MS
Yale University
Principal Investigator
clinicaltrials.gov ↗
Kathryn Hawk
Yale University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Highland Hospital
Oakland, California, United States
Andrew Herring, MD
Recruiting
San Leandro Hospital
San Leandro, California, United States
Erik Anderson, MD
Recruiting
Maine Medical Center
Portland, Maine, United States
Michael Baumann, MD
Recruiting
Cooper University Hospital
Camden, New Jersey, United States
Christopher Jones
Recruiting
University of Utah Hospital
Salt Lake City, Utah, United States
Alyrene Dorey, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Buprenorphine

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Dec 2024
Primary completion: 30 Sept 2027
Completion: 31 Dec 2028
Last update posted: 28 May 2026
Registered enrollment: 360
Registry id: NCT06494904

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.